Shots:
- Oncolytics Biotech is advancing pelareorep beyond the traditional standalone therapy model, positioning the platform as a potential immune-priming backbone capable of enhancing immunotherapies, checkpoint inhibitors, chemotherapies, and other oncology treatments across multiple difficult-to-treat tumor settings.
- The company continues generating growing survival and immune-engagement data across colorectal, pancreatic, and anal cancers, while emphasizing pelareorep’s potential to “turn cold tumors hot,” improve response durability, and strengthen long-term therapeutic outcomes through combination-based oncology strategies.
- PharmaShots welcomes Jared Kelly, CEO of Oncolytics, who shares insights on platform valuation, immune-oncology innovation, survival-focused clinical development, regulatory strategy, strategic partnerships, and the evolving commercial vision shaping the future of pelareorep within the oncology landscape.
Saurabh: You’ve now worked on two oncology platforms that spent years underappreciated by the market. Your previous experience at Ambrx ultimately resulted in a multibillion-dollar acquisition by Johnson & Johnson. What similarities are you seeing at Oncolytics, and why do these kinds of oncology valuation stories often take time to fully emerge?
Jared: Biotechnology markets often become heavily focused on short-term catalysts and near-term data events, while large pharmaceutical companies usually evaluate oncology platforms through a much longer strategic lens.
A lot of the time, the science itself has already been developing for years before broader market perception fully catches up. What changes is when clinical data, commercial relevance, regulatory clarity, manufacturing scalability, and strategic positioning all begin aligning simultaneously.
That was certainly part of the experience at Ambrx. The science had been developing for a long time before broader pharmaceutical interest accelerated in a meaningful way. Eventually, the strategic relevance of the platform became difficult for the industry to ignore.
At Oncolytics, there are similarities in the sense that pelareorep has now generated survival observations, translational data, and immune-engagement findings across multiple difficult tumor settings while oncology itself continues evolving toward combination-based treatment ecosystems.
For a long time, people viewed pelareorep primarily as a standalone therapeutic candidate. Today, the conversation around the platform has become much broader than that.
Increasingly, the discussion involves how pelareorep may fit into larger oncology ecosystems where immune engagement, durability, and combination utility are becoming critically important across multiple therapeutic categories.
From our perspective, the company has already established many of the foundational elements necessary for that broader strategic discussion to continue expanding.
Saurabh: What do you think has changed most around the way the industry is viewing pelareorep today compared to even a few years ago?
Jared: I think the industry’s understanding of immunotherapy itself has evolved substantially.
Today, many of the world’s largest oncology therapies already depend heavily on immune system activity. As a result, pharmaceutical companies are increasingly searching for platforms capable of improving immune engagement, enhancing durability, and potentially helping therapies function more effectively inside combination settings.
That naturally changes how companies evaluate platforms like pelareorep.
The conversation is no longer centered solely around whether a therapy demonstrates isolated activity in a single setting. Increasingly, the discussion involves whether a platform may improve broader treatment ecosystems already generating enormous commercial demand.
From our perspective, that shift is important because pelareorep has now generated translational evidence involving immune priming, interferon signaling, T-cell activation, and broader modulation of the tumor microenvironment across multiple studies.
At the same time, the company has reported encouraging survival observations across colorectal cancer, pancreatic cancer, and anal cancer, all of which continue contributing to the expanding strategic discussion surrounding the platform.
As additional data continue emerging, we believe the broader industry conversation surrounding pelareorep will continue evolving as well.
Saurabh: You’ve spent time both inside public markets and in major pharmaceutical transaction discussions. What do sophisticated pharma companies often see differently than the broader market?
Jared: Public markets often focus on immediacy. Pharmaceutical companies usually focus on durability.
Large pharma organizations spend a lot of time evaluating whether a platform can remain strategically relevant over long periods of time and across multiple treatment environments. They evaluate manufacturing scalability, regulatory pathways, combination utility, intellectual property positioning, and whether the biology appears consistent across different datasets.
Importantly, sophisticated pharmaceutical companies also understand that oncology development rarely progresses in a perfectly straight line. They recognize the difference between temporary market dislocations and long-term platform value.
That perspective becomes especially important in immunotherapy because treatment paradigms are still evolving very rapidly.
At Oncolytics, pelareorep is increasingly aligning with several important long-term oncology trends simultaneously, particularly surrounding immune engagement, survival durability, and combination-based treatment strategies.
The company is also reaching a much more mature phase operationally and strategically. Discussions surrounding registration-enabling studies, manufacturing capabilities, regulatory pathways, and long-term commercialization strategies are all becoming increasingly important parts of the broader story today.
Those are the types of developments sophisticated pharmaceutical participants tend to pay very close attention to.
Saurabh: A lot of the recent attention surrounding Oncolytics has involved survival observations across several difficult tumor settings. Why is survival becoming such an important part of the oncology conversation?
Jared: Because survival remains one of the most meaningful outcomes in all of oncology.
Response rates matter, but long-term survival outcomes often carry much greater significance for patients, physicians, regulators, and strategic pharmaceutical participants evaluating the broader impact of a therapy.
Additional survival time creates additional opportunities for patients to benefit from advancing science, evolving therapies, and improved standards of care.
At Oncolytics, we now have survival observations across colorectal cancer, pancreatic cancer, and anal cancer. Naturally, that starts changing the broader discussion surrounding pelareorep and the platform itself.
In metastatic colorectal cancer, the REO 022 study evaluating pelareorep in combination with FOLFIRI and bevacizumab demonstrated a median overall survival of 27 months compared with 11.2 months historically associated with standard treatment alone.
Importantly, recent FDA interactions also reinforced the agency’s willingness to prioritize meaningful survival benefit even when traditional response metrics may appear less dramatic.
Historically, sophisticated pharmaceutical companies pay very close attention when survival durability begins emerging across multiple difficult oncology settings.
And as oncology itself increasingly evolves toward durability-focused treatment paradigms, we believe those broader strategic discussions surrounding pelareorep will continue expanding.
Saurabh: Oncolytics has increasingly begun discussing registration-enabling studies and accelerated approval pathways. Does that suggest the company may be entering a fundamentally different strategic phase?
Jared: In several respects, yes.
For many years, the primary focus at Oncolytics centered on validating the science, demonstrating pelareorep’s mechanism of action, and generating clinically meaningful observations across multiple tumor settings.
Today, the company is increasingly transitioning toward demonstrating regulatory viability, commercial scalability, and potential pathways toward approval in selected indications.
That evolution is important because it reflects a much more mature phase of development for the platform.
As clinical data continue maturing, the conversation naturally begins shifting away from purely scientific validation toward areas including regulatory execution, commercialization strategy, manufacturing scalability, partnership opportunities, and long-term market positioning.
Importantly, many of those foundational elements are already being established today.
From our perspective, the broader opportunity now involves continuing to execute while allowing the industry and investment community to fully recognize the strategic evolution that has already occurred around the platform.
Saurabh: A year after joining Oncolytics, does the company feel fundamentally different to you today than the one you initially stepped into?
Jared: Absolutely. Although it may not be appreciated by the market or obvious to outside observers yet.
Before I arrived, the company was focused on a single indication that no longer had a viable path forward. Despite having great randomized breast cancer data, the registration study was not able be to financed because Enhertu displaced all other challengers in that particular indication. Sometimes great data is not enough.
Now, we have identified multiple indications within the GI tumor space where we have an opportunity to win. We have a path to registration in two GI tumors, developing data in both of those indications (PDAC and SCAC), and a confirmatory controlled study in CRC where we have the chance to deliver potentially practice changing data by the end of the year.
We also have committed resources to preclinical studies to see what new modalities outside of chemo and checkpoint inhibitors with which pelareorep can be combined effectively. The company largely ignored this part of the development process for a decade.
Finally, and perhaps most importantly—but not the headline demanding achievement like clinical data—we are focusing resources on extending the IP runway for pelareorep. We have multiple patent applications to submit and two new ones that have already been submitted since I joined. We expect a manufacturing patent to be issued very soon and multiple method of use patents to be issued before the end of 2027 that will achieve robust patent portfolio protection well into the 2040s.
Saurabh: Investors often focus heavily on financing strategy in biotechnology. How is Oncolytics approaching capital allocation and long-term shareholder alignment today?
Jared: Capital strategy remains critically important in biotechnology, particularly within the current market environment.
From our perspective, the key is maintaining discipline while continuing to advance the areas we believe matter most strategically for the platform long term.
The company has worked very carefully to prioritize regulatory clarity, manufacturing scalability, stronger controlled clinical data, and long-term strategic flexibility while avoiding financing structures that could create sustained pressure on shareholder value over time.
We also believe meaningful progress has already been made across several of those strategic priorities over the last year.
Importantly, our focus has never been simply raising capital for short-term comfort. The objective is making disciplined decisions that support the broader long-term opportunity surrounding pelareorep while preserving flexibility as the platform continues maturing operationally and clinically.
As the broader strategic profile surrounding the company continues strengthening, we believe that creates additional opportunities over time as well.
Saurabh: You’ve openly described yourself as a “transactional CEO,” which is unusual language in biotech. What does that philosophy mean to you, and how does it influence the way you’re building Oncolytics today?
Jared: The philosophy really centers around understanding how biotechnology value is ultimately realized.
Smaller biotechnology companies are often not built to independently commercialize therapies globally across every indication. The infrastructure, operational scale, and capital requirements involved are enormous.
The objective instead is building a platform compelling enough scientifically, strategically, and commercially that larger pharmaceutical organizations recognize the opportunity to accelerate development and commercialization at scale.
That means focusing not only on science, but also on manufacturing, regulatory clarity, scalability, strategic positioning, and long-term relevance inside evolving oncology ecosystems.
The Ambrx experience reinforced how quickly strategic interest can accelerate once those elements begin aligning simultaneously. Once larger pharmaceutical participants begin recognizing differentiated science supported by meaningful clinical observations, valuation narratives can evolve very quickly.
At Oncolytics, the focus is on continuing to strengthen the long-term strategic relevance of pelareorep while generating clinically meaningful outcomes that matter to patients, physicians, regulators, and potential pharmaceutical partners alike.
At the same time, successful execution of those long-term strategic objectives can also create meaningful near-term value as broader industry recognition surrounding the platform continues evolving.
We believe the company has already established many of the foundational elements necessary for that broader strategic discussion to continue expanding.
About Jared Kelly
Jared Kelly is an accomplished biotechnology executive and legal strategist with extensive experience across corporate law, capital markets, mergers & acquisitions, and business development within the life sciences industry. Prior to joining Oncolytics Biotech, he served as Head of Legal and Corporate Strategy at Ambrx, where he played a key role in the company’s $2 billion acquisition by Johnson & Johnson. Throughout his career, he has advised and led numerous strategic transactions for both public and private biotechnology companies.
At Oncolytics Biotech, Jared is focused on advancing the company’s clinical and corporate vision as it continues to develop pelareorep across multiple oncology indications. Under his leadership, the company is strengthening its position in immuno-oncology through strategic collaborations, clinical innovation, and a focused approach toward addressing challenging solid tumors.
